Immunology and Microbiology
T Cell
100%
T Cell Receptor
34%
Human Immunodeficiency Virus 1
32%
Immunotherapy
30%
Immune Response
28%
Neoantigen
27%
Cytotoxic T-Cell
27%
T-Helper Cell
23%
Immune Checkpoint Blockade
23%
Epitope
22%
Cytotoxic T Cell
14%
Vaccine Efficacy
13%
Dynamics
13%
Spike
13%
Severe Acute Respiratory Syndrome Coronavirus 2
13%
COVID-19
12%
Dendritic Cell
12%
Human Immunodeficiency Virus
11%
Cancer Immunotherapy
11%
Cell Clone
11%
Tumor-Infiltrating Lymphocytes
11%
Tumor Immunity
10%
Coronavirus
10%
Mismatch Repair
9%
Immunocompetent Cell
8%
Adoptive Immunity
7%
CD8
7%
Cell Assay
7%
Memory T Cell
7%
Colon
7%
CD4
7%
Cancer Cell
6%
Volume
5%
Vaccination Policy
5%
Th17 Cell
5%
Keyphrases
Tumor
25%
Neoadjuvant
24%
Immune Checkpoint Blockade
21%
T Cells
19%
Non-small Cell Lung Cancer (NSCLC)
16%
Neoantigen
16%
T-cell Receptor Sequencing
16%
Human Immunodeficiency Virus Type 1 (HIV-1)
14%
Resectable Lung Cancer
14%
CD8+ T Cells
14%
Cancer Immunotherapy
14%
Nivolumab
13%
CD4+ T Cells
13%
Tumor Immunity
11%
Pathological Response
11%
T Cell Receptor
11%
PD-1 Blockade
11%
Immune Response
10%
Circulating Tumor DNA (ctDNA)
9%
Durvalumab
9%
Anti-PD-1
9%
Major Pathological Response
8%
Specific T Cells
8%
T Cell Response
7%
Programmed Death-ligand 1 (PD-L1)
6%
Recurrence-free Survival
6%
In Cancer
6%
T Cell Assay
6%
Sequence Data
6%
Functional Expansion
6%
COVID-19
6%
TCR Sequencing
6%
Tumor mutation Burden
6%
Clinical Outcomes
6%
Complementarity-determining Region 3 (CDR3)
5%
CD4+ T
5%
CD-8
5%
Medicine and Dentistry
Neoplasm
44%
T Cell
36%
Lung Cancer
34%
Malignant Neoplasm
20%
T Lymphocyte Receptor
18%
Nivolumab
17%
Immune Checkpoint Blockade
16%
Immune Response
12%
Cancer Immunotherapy
12%
Immunotherapy
12%
Biological Marker
12%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Non Small Cell Lung Cancer
10%
Circulating Tumor DNA
9%
Durvalumab
9%
T-Cell Response
8%
Programmed Death-Ligand 1
8%
DNA Mismatch Repair
8%
Infection
8%
COVID-19
7%
T Cell Receptor
7%
Specific Tumor
7%
Arm
7%
Overall Survival
6%
CD8 Antigen
6%
Disease
6%
Colorectal Cancer
6%
Recurrence Free Survival
6%
T-Helper Cell
6%
Tumor Infiltrating Lymphocyte
6%
Tumor Immunity
5%
Adverse Event
5%
Coronavirus
5%
